Teclistamab-Daratumumab Combo Outperforms Standard Proteasome Inhibitor Regimens in Adjusted Myeloma Analysis
An adjusted cross-trial analysis found teclistamab plus daratumumab was associated with significantly longer progression-free and overall survival and deeper responses ...
